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Purpose: To assess quality of life and depressive status in Korean patients with Graves’ ophthalmopathy.
Methods: A cross-sectional study of 49 patients (mean age, 41 years; sex ratio, M:F=11:38) with Graves’ ophthalm-
opathy (referred to as the Graves’ group) and 48 age-matched and sex-matched controls (mean age, 40.2 years; 
sex ratio, M:F=11:37) was performed using the Korean version of the 36-item Short-Form General Health Survey 
(SF-36) questionnaire and the Beck Depression Inventory (BDI). Survey data was compared among patients with 
mild, moderately severe, and sight-threatening Graves’ ophthalmopathy and between patients with low (0 or 1) or 
high (2 or 3) Gorman scores. 
Results: Those in the Graves’ group scored significantly lower on all categories of the SF-36, as compared to the 
control group (p<0.05). The 4 patients with sight-threatening Graves’ had significantly lower scores for physical 
functioning, role limitations due to physical health, and the physical component summary of the SF-36, when 
compared with the 28 patients with mild Graves’ and the 17 patients with moderately severe Graves’ (p<0.05). 
The 17 patients in the high Gorman score group had lower physical component summary scores than the 32 pa-
tients in the low Gorman score group (p=0.03). The 16 patients with BDI scores ≥16 had significantly lower 
scores on the SF-36 and higher clinical activity scores, as compared to the 33 patients with BDI scores <16 
(p<0.05). 
Conclusions: Patients with Graves’ ophthalmopathy had reduced health-related quality of life and were more likely 
to be depressed, especially those with a sight threatening condition or significant diplopia. It is important to identi-
fy these patients to provide the necessary psychological support. 
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Graves’ ophthalmopathy is a potentially disfiguring and 
sight-threatening disease occurring in 25% to 50% of pa-
tients with Graves’ thyroid disease [1]. Clinical signs include 
lid retraction, disfiguring proptosis, extraocular muscle dys-
function, eyelid edema, conjunctival injection, chemosis, 
and optic neuropathy [2];
 symptoms include pain, swelling of 
the eyelid, a gritty sensation in the eyes, diplopia, and visual 
impairment, which profoundly impair the health-related 
quality of life of affected individuals [2-11].
Both Graves’ disease and Graves’ ophthalmopathy con-
tribute to worsened quality of life, particularly with regards 
to physical functioning, physical and emotional role func-
tioning, vitality, social functioning, and mental health [3-6]. 
In several reports, general health-related quality of life in pa-
tients with Graves’ ophthalmopathy was markedly lower 
compared to both the general population and patients with 
other chronic diseases [4,7]. In fact, the impact of Graves’ 
ophthalmopathy on quality of life has been a popular subject 
of study in Western countries, and a disease-specific vali-
dated quality of life questionnaire has been developed for 
clinical use. However, there has never been a health-related 
quality of life study using a generic questionnaire in Korean 
Graves’ ophthalmopathy patients, nor has there been a study 
using a disease-specific questionnaire which is validated and 
translated into the Korean language. In addition, in patients 
with cosmetic disfigurement or functional impairment caused 
by inflammatory symptoms, diplopia and visual dysfunction 
may be associated with emotional problems, such as depression. 
Therefore, in this study, we used the Medical Outcomes Korean J Ophthalmol Vol.24, No.2, 2010
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Study 36-Item Short Form Health Survey (SF-36) and Beck 
Depression Inventory (BDI) questionnaires, both of which 
are available in Korean versions which have been shown to 
be validated and reliable in other quality of life studies, to 
evaluate Korean patients with Graves’ ophthalmopathy of 
varying degrees of disease activity and severity. The SF-36 
items and scales are constructed using the Likert method of 
summated ratings. These ratings are summed to produce raw 
scale scores for each health concept and are transformed to a 
0 to 100 scale, with 100 indicating the best possible score. 
The BDI has 21 items scored on a 4-point Likert scale (0 to 
3). The converted scores from the questionnaires were eval-
uated with respect to the sociodemographic and clinical char-
acteristics of the participants. These objective evaluations 
will aid in the identification of patients with Graves’ oph-
thalmopathy who are more likely to need further physical and 
mental support.
Materials and Methods
Study design and recruitment of participants
This cross-sectional study included 49 patients with 
Graves’ ophthalmopathy who were followed at the Depar- 
tment of Ophthalmology, Yonsei University College of 
Medicine between July 2008 and December 2008 (referred to 
as the Graves’ group). We excluded patients who were not bi-
ochemically euthyroid to eliminate the possible effect of dys-
thyroidism on quality of life. The control group was com-
posed of healthy volunteers who were age- and sex-matched 
to the study group. Written informed consent was obtained 
from all participants after gaining approval from the 
Institutional Review Board at Yonsei University College of 
Medicine.  
Graves’ ophthalmopathy was defined as the presence of 
typical eye symptoms and signs in a patient with auto-
immune Graves’ disease. A complete ophthalmic investig- 
ation was performed, and an assessment of the severity and 
activity of Graves’ ophthalmopathy was performed [12].
 
Proptosis and eye muscle involvement were assessed using a 
Hertel exophthalmometer and the Gorman diplopia scale 
[13]. A Gorman score of 0-1 was considered low; a score of 
2-3 was considered high.
Severity of Graves’ ophthalmopathy was scored according to 
the European Group on Graves’ Orbitopathy (EUGOGO) clas-
sification system [12]. Mild Graves’ ophthalmopathy was 
defined as minor lid retraction (< 2 mm), mild soft tissue in-
volvement, exophthalmos < 21 mm, or transient (Gorman 
score 1) or no diplopia (Gorman score 0). Moderately severe 
Graves’ ophthalmopathy was defined as lid retraction ≥2 
mm, moderate or severe soft tissue involvement, exoph-
thalmos ≥21 mm, or inconstant (Gorman score 2) or constant 
diplopia (Gorman score 3). Very severe, sight-threatening 
Graves’ ophthalmopathy was defined as dysthyroid optic 
neuropathy or corneal breakdown. Patients with a history of 
optic neuropathy but who were without optic neuropathy at 
the time of the survey were included in the moderately severe 
group. Optic neuropathy was defined as the presence of disc 
swelling or pallor, a visual field defect, or relative afferent 
pupillary defect, or if visual acuity less than 0.3 in the absence 
of other reasons for sight loss [12]. Inflammation activity was 
determined using a clinical activity score based on seven 
signs of inflammation of the orbit, with each scored as absent 
(0) or present (1), with a maximum possible score of 7 [12].
At an outpatient clinic visit, patients completed a ques-
tionnaire on demographics and duration and previous treat-
ments of Graves’ ophthalmopathy and Graves’ thyroid 
disease. Quality of life was assessed by the SF-36, and de-
pressive status was evaluated by the BDI. Patients who could 
not fill out the survey themselves were provided support 
from those conducting the research. Patients were asked to 
provide any missing information at the outpatient clinic.
Survey instruments
1) Medical outcome study SF-36
The Korean version of the SF-36 was used to evaluate the 
health-related quality of life of the study participants. The 
SF-36 has been previously shown to be a credible and reli-
able instrument to measure the quality of life in study groups 
[14]. The SF-36 contains eight itemized categories and 36 
questions. The eight categories are: 1) physical functioning 
(walking, lifting); 2) role function-physical (limitations in 
ability to perform usual activities); 3) bodily pain (level of 
bodily pain or discomfort); 4) general health perceptions 
(global evaluation of health); 5) vitality (energy level or fa-
tigue); 6) social functioning (impact of health or emotional 
problems on social activities); 7) role function-emotional 
(impact of emotional problems on work or daily activities); 
and 8) mental health (anxiety, depression, sense of psycho-
logical well-being). The first four categories are grouped as 
the physical component summary, while the last four catego-
ries are grouped as the mental component summary. These 
eight categories and two summaries were converted into 
scores and evaluated with respect to the sociodemographic 
and clinical characteristics of the participants. 
2) BDI
Depression in patients with Graves’ ophthalmopathy was 
evaluated with the BDI, a standardized questionnaire of the 
cognitive, affective, and somatic symptoms of depression. 
The BDI was developed to assess the type and severity of de-
pression based on clinical symptoms [15]. The Korean version 
of the BDI has high reliability, and a score of 16 or higher has 
been suggested as the optimal cutoff score for the diagnosis 
of major depression in Korea [16,17].
 
Statistical analysis
All measures of the SF-36 were compared between the H Lee, et al. Quality of life and depression in Graves’ ophthalmopathy
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Table 1. General characteristics of patients with Graves’ ophthalmopathy at the time of survey (n=49)
Characteristics Values 
Age (yr), mean±SD  41.4±13.4
Sex (F / M) 38 (77.6) / 11 (22.4)
Duration of GO (mon) 12 (1–120)
Duration of GD (mon) 24 (1–250)
Bilateral : Unilateral manifestation (n) 35:14
Best corrected visual acuity
Right eye  20/20 (20/100–20/20)
Left eye 20/20 (20/50–20/20)
Upper lid retraction above limbus (n) 38
* 
Exophthalmometry (mm)
Right eye  18 (12–26)
Left eye  18 (12–26)
Current Gorman score of diplopia
Score 0 / 1 / 2 / 3  28 (57.1) / 4 (8.2) / 9 (18.4) / 8 (16.3)
Past history of optic neuropathy 9 (18.4)
Current state of optic neuropathy 4 (8.1)
Current clinical activity score 1 (1–6)
Score 0 / 1-3 / ≥ 4 18 (36.7) / 27 (55.1) / 4 (8.2)
Current severity by EUGOGO classification
Mild / Moderately severe / Sight-threatening  28 (57.1) / 17 (34.7) / 4 (8.2)
Previous treatment (n)
Prednisone 22
Radiotherapy 1
Decompression 11
Eye muscle surgery 4
Eye lid surgery 7
Values are presented as median (range) or number (%) unless otherwise indicated. 
EUGOGO=European Group on Graves’ Orbitopathy; GO=Graves’ ophthalmopathy; GD=Graves’ thyroid disease.
*2 of 11 eyes without retraction had previous surgeries for lid retraction.
Graves’ and control groups using independent two-sample 
t-tests. Quality of life (by SF-36 scores) and depressive status 
(by BDI scores) were compared among patients with mild, 
moderately severe, and sight-threatening Graves’ ophthalmop-
athy using one-way analysis of variance (ANOVA) and the 
Pearson chi-square test for continuous and categorical varia-
bles, respectively. SF-36 and BDI scores were also compared 
between the high and low Gorman score groups using the 
same statistical methods.
Characteristics, including age, sex, duration of Graves’ 
disease and Graves’ ophthalmopathy, Hertel exophthalmos 
values, current activity score, and severity stage by EUGOGO 
classification were compared between the patients with high 
(≥16) and low (<16) BDI scores, using the independent 
two-sample t-test and the Pearson chi-square test for con-
tinuous and categorical variables, respectively. The relation-
ship between the BDI and SF-36 scores and age, sex, dura-
tion of Graves’ disease and Graves’ ophthalmopathy, 
Gorman score, severity, and activity were examined by the 
Pearson correlation or Spearman rank correlation test. 
A p-value <0.05 was considered statistically significant in 
all analyses. Data were entered twice into a special computer 
program to minimize typing errors. Data were analyzed with 
SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA).
Results 
Demographic details and clinical characteristics of the pa-
tient population are shown in Table 1. The 49 patients in-
cluded 38 women (77.6%) and 11 men (22.4%), with a mean 
age of 41.4 years and an average duration of Graves’ oph-
thalmopathy of 12 months. Nine patients (18.4%) had a his-
tory of optic neuropathy, and four patients (8.1%) had optic 
neuropathy at the time of the survey. The patients were asked 
“What is the main cause of emotional distress now?” with three 
possible answers: disfiguring change, functional impairment, or 
both equally distressful. Twenty patients (40.8%) responded 
with disfiguring change, 14 patients (28.6%) responded with 
functional impairment, and 15 patients (30.6%) reported 
both. The control group included 48 individuals ages 23 to 76 
years (mean age, 40.2 years sex ratio, M:F=11:37). As shown 
in Fig. 1, the Graves’ group scored lower on all categories of 
the SF-36, as compared to the control group (p<0.05). 
In comparing the SF-36 and BDI scores among the mild, Korean J Ophthalmol Vol.24, No.2, 2010
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Fig. 1. Comparison between quality of life in patients with Graves’
ophthalmopathy (GO) (n=49) and normal individuals (n=48). All 
the subscales of Medical Outcomes Study Short-Form 36 (SF-36) 
were significantly lower in patients with GO than in normal 
individuals. 
Table 2. SF-36 subscales and BDI for the mild, moderately severe, and sight-threatening group
SF-36 Mild (n=28) Moderately severe (n=17) Sight-threatening (n=4) p-value
Physical functioning 81.6±18.6 78.8±17.0 53.7±11.0 0.018
*
Role limitations due to physical health 62.5±36.3 58.8±34.2 6.3±12.5 0.014
*
Bodily pain 61.3±27.7 62.6±22.9 47.3±21.6 0.555
General health perceptions 48.3±18.1 43.8±13.6 41.0±14.1 0.667
Vitality 43.4±22.8 42.9±14.6 40.3±17.5 0.956
Social functioning 68.3±24.9 69.9±14.7 56.3±7.2 0.505
Role limitations due to mental health 65.5±41.1 60.8±41.2 53.4±38.5 0.349
Mental health 57.6±21.6 53.6±14.9 51.0±20.8 0.404
Physical component summary 45.5±7.9 44.9±7.2 34.6±7.6  0.035
*
Mental component summary 41.2±11.0 40.0±7.4 40.8±6.1 0.922
BDI score
16 or more, n (%)
11.3±7.3
7 (25.0)
13.6±7.0
7 (41.2)
15.5± 10.0
2 (50.0)
0.412
0.418
Values are presented as mean±SD unless otherwise indicated. 
BDI=Beck Depression Inventory; SF-36=Medical Outcomes Study Short-Form 36. 
*p<0.05. 
moderately severe, and sight-threatening Graves’ groups 
(Table 2), the four patients with sight-threatening Graves’ 
ophthalmopathy had significantly lower scores for physical 
functioning, role function-physical, and the physical compo-
nent summary than the 28 patients with mild and 17 patients 
with moderately severe Graves’ ophthalmopathy (p<0.05). 
Patients with mild and moderately severe Graves’ ophthalm-
opathy had similar scores for most SF-36 items. A higher BDI 
score was observed in patients with sight-threatening 
Graves’ ophthalmopathy, as compared to patients with mild or 
moderately severe Graves’ ophthalmopathy, and a higher pro-
portion of patients with sight-threatening Graves’ had de-
pression (BDI score ≥16) than did patients with mild and 
moderately severe Graves’ (although this difference was not 
statistically significant). 
Nine patients who were previously diagnosed with optic 
neuropathy but recovered after orbital decompression sur-
gery or high-dose steroid treatment were included in the 
moderately severe group. No significant difference in SF-36 
and BDI scores were observed between the 9 patients with 
previously diagnosed optic neuropathy and the remaining 8 
patients in the moderately severe category (data now shown). 
The 17 patients with a high Gorman score had a sig-
nificantly lower physical component summary score on the 
SF-36 than the 32 patients with a low Gorman score 
(p=0.035) (Table 3). Compared to the low Gorman score 
group, the high Gorman score group also had lower subscale 
scores on the SF-36 for all measures but vitality, the mental 
component summary score, and mean BDI score (albeit 
without statistical significance). 
Sixteen patients (32.7%) had BDI scores ≥16 (indicative of 
clinical depression). These patients had significantly lower 
scores on the eight subscales and two summary scores of the 
SF-36, as well as higher clinical activity scores, as compared 
to the 33 patients with low BDI scores (p<0.05) (Table 4). No 
significant differences were observed between the high and 
low BDI score groups with respect to age, sex, duration of 
Graves’ disease or Graves’ ophthalmopathy, or Hertel 
exophthalmos values. There were no significant differences 
between patients with high and low BDI scores in terms of 
current severity stage by EUGOGO classification, main 
cause of distress, or history of optic neuropathy (p>0.05). 
Although not statistically significant, it is interesting that 
50% of patients in the depressed group (BDI≥16) reported 
that both functional impairment and facial disfigurement 
equally affected their emotional distress, whereas only 
18.2% of patients in the non-depressed group (BDI<16) re-
ported that both parameters were equally distressing 
(p=0.058) (Table 4). In addition, no significant correlation 
was observed between BDI score and age (r=-0.025, p=0.863), 
sex (r=0.090, p=0.538), duration of Graves’ disease (r=0.113, 
p=0.441), duration of Graves’ ophthalmopathy (r=-0.863, 
p=0.556), Gorman score (r=0.203, p=0.163), severity (r=0.209, 
p=0.150), or disease activity (r=0.201, p=0.166). However, H Lee, et al. Quality of life and depression in Graves’ ophthalmopathy
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Table 3. SF-36 subscales and BDI for the higher and lower Gorman score groups 
SF-36 Gorman score 0,1 (n=32) Gorman score 2,3 (n=17) p-value
Physical functioning 81.9±17.8 71.8±19.6 0.086
Role limitations due to physical health 61.7±35.3 47.1±39.4 0.209
Bodily pain 64.6±25.2 53.1±25.3 0.141
General health perceptions 49.3±16.7 41.8±14.6 0.115
Vitality 42.9±21.3 44.4±16.5 0.794
Social functioning 68.4±21.5 66.9±20.2 0.817
Role limitations due to mental health 63.5±40.9 56.9±42.1 0.598
Mental health 56.6±20.7 55.3±16.4 0.807
Physical component summary 46.2±7.5 40.9±8.2 0.035
*
Mental component summary 40.5±9.9 41.3±8.7 0.773
BDI score
16 or more, n (%)
10.9±5.9
8 (25.0)
15.2±9.1
8 (47.0)
0.054
0.117
Values are presented as mean± SD unless otherwise indicated. 
BDI=Beck Depression Inventory; SF-36=Medical Outcomes Study Short-Form 36. 
*p<0.05. 
Table 4. Comparison of the characteristics of depressed and non-depressed patients with Graves’ ophthalmopathy
Characteristics BDI <16 (n=33) BDI ≥16 (n=16) p-value
Age (yr)  40.2±13.6 43.8±12.9 0.390
Sex 
Female  26 (78.8) 12 (75.0) 0.766
Duration of GD (mon) 33.2±36.9 48.4±62.46 0.380
Duration of GO (mon) 19.1±19.9 22.2±31.1 0.717
Exophthalmometry (mm)
Right 17.8±3.1 18.7±3.6 0.439
Left 17.7±3.2 19.2±3.2 0.134
Current severity by EUGOGO classification
Mild / Moderately severe / Sight-threatening 21 / 10 / 2 7 / 7 / 2 0.396
Current activity score  1.0±1.3 2.3±1.7  0.009
*
4 or more 2 (6.0) 2 (12.5)
Main cause of emotional distress
Disfiguring change 10 (30.3) 4 (25.0) 0.058
Functional impairment   17 (51.5) 4 (25.0)
Both equally distressful 6 (18.2) 8 (50.0)
Past history of optic neuropathy 4 (12.1) 5 (31.3) 0.130
SF-36 
Physical functioning  84.1±16.5 66.6±18.3 0.003
*
Role limitations due to physical health  69.7±32.9 29.7±30.6 <0.001
*
Bodily pain  67.9±25.7 45.4±17.9 0.001
*
General health perceptions  51.6±14.8 36.6±14.7 0.002
*
Vitality  47.1±20.3 35.9±15.9 0.043
*
Social functioning  73.1±21.2 57.0±15.8 0.005
*
Role limitations due to mental health  71.7±39.2 39.6±36.9 0.009
*
Mental health  61.8±18.8 44.5±14.4 0.001
*
Physical component summary  47.2±6.8 38.7±7.8 0.001
*
Mental component summary  43.3±9.5 35.5±6.9 0.002
*
Values are presented as mean±SD or number (%). 
BDI=Beck Depression Inventory; SF-36=Medical Outcomes Study Short-Form 36; GD=Graves’ thyroid disease; GO=Graves’ ophthalmopathy. 
*p<0.05. Korean J Ophthalmol Vol.24, No.2, 2010
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the BDI scores had significant negative correlations with all 
subscale scores on the SF-36 (data not shown, p<0.05). 
Discussion
Because the goal of the treatment of Graves’ ophthalmop-
athy is to improve functioning and make patients look and 
feel better, the functional capacity and quality of life should 
be evaluated. The impact of Graves’ ophthalmopathy on 
quality of life has been the subject of several studies. The first 
article on quality of life in patients with Graves’ ophthalmop-
athy was published by Gerding et al [14]. using a general 
quality of life questionnaire. In that study, the patient group 
was found to have lower score compared to a large reference 
group; however, the correlations between scores on general 
quality of life questionnaires and duration, severity, or activ-
ity of Graves’ ophthalmopathy were low [14]. An Australian 
group conducted a cross-sectional study using a modified in-
strument to measure quality of life in patients with Graves’ 
ophthalmopathy [15], finding a significant relationship be-
tween impaired quality of life and severity of ophthalmop-
athy, as measured by NOSPECS [5]. Yeatts [18] found a re-
duction in quality of life for both physical and mental health 
in patients with Graves’ ophthalmopathy using National Eye 
Institute visual functioning questionnaires (NEI-VFQ). 
Bradley et al. [19] used the NEI-VFQ to evaluate patients 
with Graves’ ophthalmopathy and found that these patients 
were especially impaired on the mental health subscale. Farid 
et al. [20]
 used the Profile of Mood State Survey in 48 patients 
with Graves’ ophthalmopathy and reported that patients with 
moderate to severe Graves’ ophthalmopathy exhibited sig-
nificantly greater emotional distress than did patients with 
mild Graves’ ophthalmopathy.
To our knowledge, this is the first study that assesses both 
quality of life and the frequency and severity of depressive 
symptoms in Korean patients with Graves’ ophthalmopathy, 
although we did not use a Graves’ ophthalmopathy-specific 
questionnaire. The results show that patients with Graves’ 
ophthalmopathy had significantly lower quality of life scores 
than individuals in the age-and sex-matched control group, 
and that these scores were comparable to those of patients 
with other chronic diseases [21-23].
 
The prevalence of depression in this study was 32.7%, 
much higher than the 10% prevalence in the general pop-
ulation [24].
 This is higher than the prevalence of depression 
found in patients with retinitis pigmentosa [20]
 and similar to 
patients with diabetes [25], cancer [26],
 or myocardial in-
farction [27]. Studies by Kahaly et al. [28] showed that 45% 
of patients with Graves’ ophthalmopathy have anxiety or de-
pression, and patients with Graves’ ophthalmopathy score 
significantly lower than controls on measures of emotional 
role limitation and mental health.
 We assumed that both cos-
metic disfigurement and functional impairment play key 
roles in causing emotional distress (including depression) in 
patients with Graves’ ophthalmopathy. Recently, Paik and 
Yang [29] showed that patients with moderate to severe oph-
thalmopathy reported significantly greater emotional distress 
than patients with mild ophthalmopathy, according to the 
Korean Profile of Mood States survey. In particular, patients 
whose disfiguring signs were predominantly due to proptosis 
had significantly greater emotional stress, as compared to pa-
tients in whom diplopia was predominant. In our study, how-
ever, no differences in Hertel exophthalmos values were ob-
served between the high and low BDI score groups. As cos-
metic disfigurement is acknowledged differently between 
patients and because there are other determinants of cosmetic 
disfigurement beyond proptosis (such as lid retraction, lid 
swelling, and conjunctival injection), we surveyed results 
from somewhat subjective self-questionnaires regarding the 
main cause of distress. More patients in the depressed group 
(BDI ≥16, 50%) reported that both functional impairment 
and facial disfigurement equally contribute to their emo-
tional distress than did those in the non-depressed group 
(BDI <16, 18.2%) with borderline significance (p=0.058). 
Results from the current study are not consistent with the re-
cent report by Paik and Yang [29] possibly because of differ-
ent survey instruments and methods of analysis. We found 
that patients with Graves’ ophthalmopathy with depression 
had significantly lower quality of life (with lower SF-36 
scores for all subscales), as compared to those without 
depression. Additionally, the BDI scores in patients with 
Graves’ ophthalmopathy were negatively correlated with the 
SF-36 score. Interestingly, patients with Graves’ ophthalm-
opathy and depression had significantly higher clinical activ-
ity scores, as compared with those without depression, in-
dicating that the severity of depression is associated with cur-
rent inflammatory symptoms, such as pain, swelling, and 
chemosis (p<0.05).
Patients in the high Gorman score group had significantly 
lower physical component summary scores than the patients 
in the low Gorman score group. Although the patients in the 
high Gorman score group had a higher mean BDI score than 
patients in the low Gorman score group, this difference was 
not statistically significant. Patients with bothersome dip-
lopia are significantly impaired in their social and vocational 
functions because they cannot establish single binocular vi-
sion in primary gaze and create the largest possible field of 
single binocular vision [30]. Hatt et al. [31] found that me-
dian scores on the psychosocial subscale were significantly 
lower in patients with strabismus, as compared to visually 
normal adults.Successful treatment of strabismus, although not 
easy, significantly improves quality of life. 
We found that patients with sight-threatening Graves’ oph-
thalmopathy had lower SF-36 scores and higher BDI scores 
than those with mild and moderately severe Graves’ 
ophthalmopathy. The SF-36 and BDI scores were not sig-
nificantly different between the nine patients who were pre-
viously diagnosed with optic neuropathy but had recovered 
after orbital decompression surgery or high-dose steroid 
treatment and the others in the moderately severe group. H Lee, et al. Quality of life and depression in Graves’ ophthalmopathy
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Although patients may have low quality of life and high de-
pressive status due to sight-threatening severity, prompt and 
proper treatment will lead to better quality of life and elimi-
nate depression. 
Our study has several important limitations. The SF-36 is 
very broadly based, containing items to measure general as-
pects of health-related quality of life. It may miss relevant items 
for a specific disease and may not be able to measure small but 
clinically important changes for Graves’ ophthalmopathy. 
Therefore, a Korean version of a disease-specific quality of 
life questionnaire for patients with Graves’ ophthalmopathy 
is warranted. We did not diagnose depression using conven-
tional diagnostic criteria, instead measuring symptoms of de-
pression in patients with Graves’ ophthalmopathy using the 
BDI self-reported questionnaire, as the BDI is a good screen-
ing method for depression [32].
 
This study demonstrates that Graves’ ophthalmopathy can be 
a risk factor for depression and reduced quality of life. 
Patients with Graves’ ophthalmopathy that is sight-threat-
ening or associated with significant diplopia showed the 
greatest impairment in quality of life. In addition, patients 
with depression were likely to have active inflammation. Our 
findings suggest the importance of assessing and managing 
the psychosocial burden and impairments in quality of life in 
patients with Graves’ ophthalmopathy and suggest that they 
should be considered part of standard follow-up. Psychological 
support or treatment is critical in the patient with Graves’ 
ophthalmopathy to eliminate depression and improve quality 
of life. Hence, a multidisciplinary approach, including oph-
thalmology, endocrinology, and psychiatry, is critical for pa-
tients with Graves’ ophthalmopathy. Such an integrated ap-
proach will help to define the extent of the problem and how 
patients adapt to living with the disease. In the future, ex-
tensive and randomized clinical studies are necessary for the 
assessment of the clinical effect of this multidisciplinary 
approach. 
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